申请人:Howes David Peter
公开号:US20050009775A1
公开(公告)日:2005-01-13
Protide compounds of formula (I)
wherein X represents H, F, N
3
, NH
2
, —CN, or —OMe; X
1
represents O or NR
7
; X
2
represents O, NH, NR
6
or S, or when X
3
is O then X
2
is absent; X
3
is absent, or when X
1
is O then X
3
represents O; R
1
represents hydrogen; optionally substituted C
1-6
alkyl; optionally substituted aryl; or optionally substituted heteroaryl; R
2
represents hydroxy, OCOR
6
, or OCO
2
R
6
; R
3
represents H, optionally substituted C
1-6
alkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl; R
4
and R
5
are independently selected from hydrogen, optionally substituted C
1-6
alkyl, optionally substituted aryl, or optionally substituted aralkyl; R
6
represents optionally substituted C
1-6
alkyl or optionally substituted aryl; R
7
represents H, optionally substituted C
1-6
alkyl, or optionally substituted aryl, wherein when R
4
and R
7
are each alkyl they may be linked to form a 5- or 6-membered ring;
B represents (a), (b), (c), or (d)
wherein Z represents O or S; R
8
represents H, halo, C
2-4
alkynyl, trifluoromethyl, C
1-3
alkoxy, hydroxy, methylthio, amino, nitro, or C
1-3
alkyl wherein the C
1-3
alkyl may be optionally substituted by hydroxy, halo, amino, or OR
10
wherein R
10
represents C
1-6
alkyl optionally substituted by aryl which may itself be optionally substituted; and R
9
represents H, halo, hydroxy, OR
6
, SR
6
or NR
3
R
3
;
are useful in the treatment of viral infection, particularly HCV infection.
式(I)的原肽化合物
其中 X 代表 H、F、N
3
、NH
2
、-CN 或-OMe; X
1
代表 O 或 NR
7
; X
2
代表 O、NH、NR
6
或 S,或当 X
3
为 O 时,则 X
2
不存在;X
3
不存在,或者当 X
1
为 O 时,则 X
3
代表 O;R
1
代表氢
1-6
烷基;任选取代的芳基;或任选取代的杂芳基; R
2
代表羟基、OCOR
6
或 OCO
2
R
6
; R
3
代表 H、任选取代的 C
1-6
烷基、任选取代的芳基、任选取代的杂芳基或任选取代的杂环基;R
4
和 R
5
独立选自氢、任选取代的 C
1-6
烷基、任选取代的芳基或任选取代的芳烷基;R
6
代表任选取代的 C
1-6
烷基或任选取代的芳基;R
7
代表 H、任选取代的 C
1-6
烷基或任选取代的芳基,其中当 R
4
和 R
7
均为烷基时,它们可连接形成 5 或 6 元环;
B 代表(a)、(b)、(c)或(d)
其中 Z 代表 O 或 S; R
8
代表 H、卤素、C
2-4
炔基、三氟甲基、C
1-3
烷氧基、羟基、甲硫基、氨基、硝基或 C
1-3
烷基,其中 C
1-3
烷基可任选被羟基、卤代、氨基或 OR 取代
10
其中 R
10
代表 C
1-6
烷基,可任选被芳基取代,芳基本身也可任选被取代;以及 R
9
代表 H、卤代、羟基、OR
6
、SR
6
或 NR
3
R
3
;
可用于治疗病毒感染,尤其是丙型肝炎病毒感染。